Vorinostat
Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)
National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daunomycin National Cancer Institute (NCI) | Phase 3 | BBB |
Fludarabine Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 | BBB |
Idarubicin Bruno C. Medeiros | Phase 2 | BBB |
Cytarabine Alice Mims | Phase 3 | BBB |
Etoposide Alice Mims | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Vorinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →